Cancer treatment-induced bone loss.

Cancer treatment-induced bone loss. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cancer treatment-induced bone loss. Abstract Text:

Robert A Adler,Robert A Adler,

PURPOSE OF REVIEW: Patients treated for cancer may be at risk for osteoporosis and fracture. Evaluation and treatment of patients with cancer treatment-induced bone loss should lead to fewer fractures. This review will help clinicians learn to identify, evaluate and treat cancer patients at risk. RECENT FINDINGS: Survivors of childhood cancers and patients made hypogonadal by treatment for breast or prostate cancer are clearly at risk for osteoporosis and fracture. Use of aromatase inhibitors rather than tamoxifen for breast cancer will likely lead to more osteoporosis. Bisphosphonates prevent bone loss in many patients at risk. SUMMARY: For many cancer patients, treatment with calcium, vitamin D, and bisphosphonates will likely decrease the consequences of cancer treatment-induced bone loss, namely fractures.

Cancer treatment-induced bone loss. Publishing Authors By Initials

RA Adler,RA Adler,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cancer treatment-induced bone loss. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current opinion in endocrinology, diabetes, and ob

VOLUME: 14

Page Numbers: 442-5

Journal Abbreviation:

ISSN: 1752-2978

DAY: 5

MONTH: Dec

YEAR: 2007

Cancer treatment-induced bone loss. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101308636

Cancer treatment-induced bone loss. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cancer treatment-induced bone loss. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cancer treatment-induced bone loss.

AFFILIATION: McGuire Veterans Affairs Medical Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23249, USA. robert.adler@va.gov

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Endocrinol Diabetes

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cancer treatment-induced bone loss Related Publications

• Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.
• Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
• Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease.
• Cancer treatment-induced bone loss.
• Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: the Study of Women's Health Across the Nation (SWAN).
• Cutaneous necrotizing vasculitis associated with hepatitis C virus infection.
• Defining mild cognitive impairment in Parkinson's disease.
• Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.
• Effective permeability of fractured porous media with power-law distribution of fracture sizes.
• Effects of follistatin overexpression on cell differentiation in the chick embryo retina.
• Effects of temperature on gene expression patterns in Leptospira interrogans serovar Lai as assessed by whole-genome microarrays.
• Enhanced expression of mucin genes in a guinea pig model of allergic asthma.
• Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II.
• Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease.
• Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.
• Histone acetylation at the Ifng promoter in tolerized CD4 cells is associated with increased IFN-gamma expression during subsequent immunization to the same antigen.
• Influence of the Stern layer on electrokinetic phenomena in porous media.
• Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits.
• Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones.
• Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
• Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test.
• Perceived socioeconomic status: a new type of identity that influences adolescents' self-rated health.
• Pollinator and herbivore attraction to cucurbita floral volatiles.
• Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.
• Teaching resources. A biochemical assay for acetylcholinesterase activity in PC12 cells.
• The application of the HapMap to diabetic nephropathy and other causes of chronic renal failure.
• The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats.
• The flare gene, which encodes the AIP1 protein of Drosophila, functions to regulate F-actin disassembly in pupal epidermal cells.
• Treatment of cavernous sinus tumors with linear accelerator radiosurgery.
• [Potential therapy for mucus hypersecretion in chronic obstructive pulmonary disease]